Cronograma de promoção Vincerx Pharma, Inc.
Agenda avançada
Gráfico simples
Sobre a empresa Vincerx Pharma, Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. mais detalhes| IPO date | 2020-05-27 |
|---|---|
| ISIN | US92731L1061 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://vincerx.com |
| Цена ао | 5.12 |
| Alteração de preço por dia: | +5.49% (0.1839) |
|---|---|
| Alteração de preço por semana: | -6.33% (0.2071) |
| Alteração de preço por mês: | -26.52% (0.264) |
| Alteração de preço em 3 meses: | -71.68% (0.685) |
| Mudança de preço em seis meses: | -73.68% (0.737) |
| Mudança de preço por ano: | -83.56% (1.18) |
| Mudança de preço em 3 anos: | -98.06% (10) |
| Mudança de preço em 5 anos: | +0% (0.194) |
| Mudança de preço em 10 anos: | +0% (0.194) |
| Mudança de preço desde o início do ano: | -44.57% (0.35) |
|
|
Subestimação
|
Eficiência
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Obrigação
|
Impulso de crescimento
|
|||||||||||||||||||||||||||||||||||||
| Instituições | Volume | Compartilhar, % |
|---|---|---|
| Goldman Sachs Group Inc | 1709656 | 7.98 |
| Sage Rhino Capital LLC | 1703413 | 7.95 |
| Long Focus Capital Management, LLC | 1098753 | 5.13 |
| Bank of America Corporation | 1082863 | 5.06 |
| Rock Springs Capital Management, LP | 891719 | 4.16 |
| Vanguard Group Inc | 513420 | 2.4 |
| Kingdon Capital Management LLC | 385000 | 1.8 |
| Rubric Capital Management LP | 354377 | 1.65 |
| Point72 Asset Management, L.P. | 344827 | 1.61 |
| ExodusPoint Capital Management, LP | 324119 | 1.51 |
| Supervisor | Cargo | Pagamento | Ano de nascimento |
|---|---|---|---|
| Dr. Ahmed M. Hamdy M.D. | Co-Founder, Chairman & CEO | 657.54k | 1965 (60 anos) |
| Dr. Raquel E. Izumi Ph.D. | Co-Founder, President, COO, Secretary & Director | 591.54k | 1970 (55 anos) |
| Mr. Alexander A. Seelenberger M.B.A. | Chief Financial Officer | 491.69k | 1979 (46 anos) |
| Mr. Tom C. Thomas J.D. | Founder, General Counsel & Chief Legal Officer | 444.14k | 1960 (65 anos) |
| Dr. John C. Byrd M.D. | Founder & Chairman of Scientific Advisory Board | N/A | |
| Dr. Hans-Georg Lerchen Ph.D. | Chief Scientific Officer | N/A | |
| Ms. Gabriela Jairala | Vice President of Investor Relations & Corporate Communications and Chief of Staff | N/A | |
| Ms. Melissa Merrick SPHR | Senior Director of People & Culture and Head of Human Resource | N/A | |
| Dr. Beatrix Stelte-Ludwig Ph.D. | Executive Chief Development Officer | N/A | |
| Ms. Karen Quarford M.B.A. | Vice President of Quality Operations & Compliance |
Endereço: United States, Palo Alto. CA, 260 Sheridan Avenue - abrir no Google Maps, abrir mapas Yandex
Site: https://vincerx.com
Site: https://vincerx.com
